Sunday 18 October 2026
Export CYTT’s income statement to Excel — free account
Cyteir Therapeutics, Inc.
CYTT Healthcare Biotechnology
Dividend growth for five consecutive years.
3.01
0.00
0.00%
Follow CYTT
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Older periods | |
|---|---|---|---|---|---|
| (23.80%) | (27.94%) | (28.72%) | (27.62%) |
+8 more TTM periods Free account |
|
| (22.70%) | (26.38%) | (27.36%) | (26.42%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(26.62%) | (31.93%) | (32.98%) | (31.64%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.71) | (0.94) | (1.14) | (1.21) | |
Free Cash Flow |
(25.49) | (33.51) | (40.50) | (42.84) | |
Capital Expenditures |
0.30 | 0.29 | 0.03 | (0.31) | |
| Other line items | |||||
Cash ROIC |
(10.02%) | (12.82%) | (14.88%) | (14.60%) | |
Accounts Payable Turnover |
0.77 | 0.38 | 0.49 | 0.61 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
222.33 | 523.27 | 237.92 | 465.22 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(6.78) | (9.50) | (13.10) | (22.84) | |
Operating CF/Net income |
0.78 | 0.83 | 0.91 | 0.92 | |
Depreciation/Fixed assets |
5.12 | 2.78 | 2.04 | 0.39 | |
Capex/Depreciation |
0.56 | 0.49 | 0.04 | (0.47) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.72) | (0.95) | (1.14) | (1.21) | |
Capex per Share |
0.01 | 0.01 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates